Novartis Trading Volume Surges 74% to 293rd Position as FDA Approves New Therapy
1min read On March 28, 2025, novartis (NVS) saw a trading volume of 2.85 billion, marking a 74.13% increase from the previous day. This surge placed Novartis at the 293rd position in terms of trading volume for the day. The stock price of Novartis rose by 1.05%, marking the second consecutive day of gains, with a total increase of 2.21% over the past two days.
Novartis received approval from the FDA for its radioligand therapy, Pluvicto, for earlier use before chemotherapy in patients with PSMA-positive metastatic castration-resistant prostate cancer. This approval is a significant milestone for Novartis, as it expands the therapeutic options available for patients with this aggressive form of prostate cancer. The earlier use of Pluvicto before chemotherapy could potentially improve patient outcomes by providing a more targeted and effective treatment option.
Novartis continues to invest in its research and development efforts, with a focus on innovative therapies and technologies. The company recently posted job openings for various positions within its Biomedical Research division, including roles in project management, molecular pathology, and drug product development. These positions highlight Novartis' commitment to advancing its pipeline of biologics therapies and other innovative treatments.
Novartis' strategic focus on early research project leadership and the development of new antibody, protein, nucleic acid, and virus-based molecules is evident in its recent job postings. The company is seeking highly motivated scientists and leaders to drive the successful execution of a wide range of traditional biologics projects, including cell and gene therapies and siRNA therapies. This focus on innovation and collaboration is expected to contribute to Novartis' continued growth and success in the biopharmaceutical industry.
Ask Aime: What is the impact of Novartis' trading volume surge on the pharmaceutical sector?
